Home » Stocks » iBio, Inc.

iBio, Inc. (IBIO)

Stock Price: $3.80 USD -0.26 (-6.40%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 532.46M
Revenue (ttm) 1.31M
Net Income (ttm) -17.40M
Shares Out 143.88M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.80
Previous Close $4.06
Change ($) -0.26
Change (%) -6.40%
Day's Open 3.93
Day's Range 3.62 - 4.14
Day's Volume 17,369,814
52-Week Range 0.05 - 7.45

More Stats

Market Cap 532.46M
Enterprise Value 556.00M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 143.88M
Float 109.49M
EPS (basic) -1.19
EPS (diluted) -0.98
FCF / Share -0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.94M
Short Ratio 0.12
Short % of Float 3.32%
Beta -5.45
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 405.53
PB Ratio 147.30
Revenue 1.31M
Operating Income -15.13M
Net Income -17.40M
Free Cash Flow -14.38M
Net Cash -23.54M
Net Cash / Share -0.17
Gross Margin 153.69%
Operating Margin -1,152.09%
Profit Margin -2,987.40%
FCF Margin -1,094.97%
ROA -23.99%
ROE -320.62%
ROIC -27.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$30.00*
Low
30.0
Current: $3.80
High
30.0
Target: 30.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.020.440.390.951.850.211.011.280.52-
Revenue Growth354.5%12.69%-58.44%-48.78%802.93%-79.64%-21.14%145.54%--
Gross Profit2.020.440.390.951.850.211.011.280.52-
Operating Income-15.79-14.23-14.27-9.89-6.67-3.84-6.67-9.33-9.65-4.59
Net Income-17.59-16.11-14.53-9.76-6.63-3.67-6.20-5.68-12.14-6.08
Shares Outstanding18.9310.638.918.107.156.304.943.953.102.73
Earnings Per Share-0.94-1.54-1.64-1.20-0.90-0.60-1.30-1.40-3.90-2.20
Operating Cash Flow-13.98-13.48-13.16-8.07-4.73-4.12-4.85-6.01-5.34-2.35
Capital Expenditures-0.99-1.08-1.59-0.07-0.22-0.26-0.20-0.25-0.09-
Free Cash Flow-14.97-14.56-14.76-8.14-4.94-4.38-5.04-6.26-5.43-2.35
Cash & Equivalents4.4215.938.0923.019.493.594.415.622.840.91
Total Debt24.8825.0825.2725.44------
Net Cash / Debt-20.46-9.15-17.18-2.429.493.594.415.622.840.91
Assets30.5943.0836.0151.6012.496.499.359.777.344.93
Liabilities28.1326.9227.1027.561.260.404.293.607.143.85
Book Value2.4616.178.919.9411.236.105.076.170.201.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name iBio, Inc.
Country United States
Employees 55
CEO Thomas F. Isett

Stock Information

Ticker Symbol IBIO
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: IBIO

Description

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.